P12931 (SRC_HUMAN) Homo sapiens (Human)

Proto-oncogene tyrosine-protein kinase Src UniProtKBInterProSTRINGInteractive Modelling

536 aa; Sequence (Fasta) ; (Isoform 2; Isoform 3); 3 identical sequences: Pan troglodytes: A0A6D2Y674, K7B763; Gorilla gorilla gorilla: G3QWW0

Available Structures

70 Experimental Structures

DescriptionPDB IDOligo-stateRangeLigands
Crystal structure of SH3:RGT complex Heteromer
P05106;
87-144
Assess
Src-derived mutant peptide inhibitor complex of PTP1B Heteromer
P18031;
527-532
Assess
Crystal structure of the tyrosine kinase binding domain of Cbl-c in complex with phospho-Src peptide Heteromer
Q9ULV8;
417-421
CA;
Assess
PTPN21 PTP domain C1108S mutant in complex with SRC pTyr530 peptide Heteromer
Q16825;
528-531
Assess
Src-derived peptide inhibitor complex of PTP1B Heteromer
P18031;
529-531
Assess
C-Src in complex with compound 9homo-2-mer260-536
C0N;
Assess
C-src (SH2 domain) complexed with ace-formyl phosphotyr-glu-(n,n-dipentyl amine)homo-2-mer144-249
Assess
C-SRC (SH2 DOMAIN WITH C188A MUTATION) COMPLEXED WITH ACE-FORMYL PHOSPHOTYR-GLU-(N,N-DIPENTYL AMINE)homo-2-mer144-249
Assess
C-SRC (SH2 DOMAIN) COMPLEXED WITH ACE-PHOSPHOTYR-GLU-(N,N-DIPENTYL AMINE)homo-2-mer145-249
Assess
C-SRC (SH2 DOMAIN) COMPLEXED WITH ACE-MALONYL TYR-GLU-(N,N-DIPENTYL AMINE)homo-2-mer145-249
Assess
C-SRC (SH2 DOMAIN) COMPLEXED WITH ACE-PHOSPHOTYR-GLU-(N-ME(-(CH2)3-CYCLOPENTYL))homo-2-mer145-249
Assess
C-SRC (SH2 DOMAIN) COMPLEXED WITH ACE-PHOSPHOTYR-GLU-(3-BUTYLPIPERIDINE)homo-2-mer146-249
Assess
Human cSrc SH3 Domain in complex with Choline Kinase fragment 60-69homo-2-mer87-144
ZN;
Assess
CRYSTAL STRUCTURE OF HUMAN TYROSINE-PROTEIN KINASE C-SRCmonomer86-536
Assess
Structure of unphosphorylated c-Src in complex with an inhibitormonomer86-536
SO4;MPZ;
Assess
CRYSTAL STRUCTURE OF HUMAN TYROSINE-PROTEIN KINASE C-SRC, IN COMPLEX WITH AMP-PNPmonomer87-536
ANP;
Assess
Structure of Human c-Src Tyrosine Kinase (Thr338Gly Mutant) in Complex with N6-benzyl ADPmonomer87-536
NBS;
Assess
The structure of 1NA in complex with Src T338Gmonomer87-534
0J9;
Assess
Src kinase in complex with a quinazoline inhibitormonomer88-532
H8H;
Assess
Crystal structure of Src kinase domain in complex with Purvalanol Amonomer258-536
P01;
Assess
Crystal structure of Src kinase domain in complex with CGP77675monomer259-536
S03;
Assess
Src kinase bound to eCF506 trapped in inactive conformationmonomer260-536
EDO;UCW;
Assess
human Src kinase bound to kinase inhibitor bosutinibmonomer260-536
DB8;
Assess
The complex of Src with GW8510monomer260-536
L1N;
Assess
SRC kinase bound to covalent inhibitormonomer260-536
6H3;
Assess
Src M314L T338M double mutant bound to kinase inhibitor bosutinibmonomer260-536
DB8;
Assess
Src M314L T338M double mutant bound to kinase inhibitor bosutinibmonomer260-536
DB8;
Assess
Human Src A403T mutant bound to kinase inhibitor bosutinibmonomer260-536
DB8;
Assess
C-term tail segment of human tyrosine kinase (258-533)monomer261-536
Assess
DGY-06-116, a novel and selective covalent inhibitor of SRC kinasemonomer261-536
HVY;
Assess
Src Kinase Domain in complex with ponatinibmonomer261-536
0LI;TRS;GOL;
Assess
Crystal structure of Src kinase domainmonomer264-536
Assess
Src kinase in complex with inhibitor AP23451monomer260-531
24A;
Assess
Src kinase in complex with inhibitor AP23464monomer260-524
HET;
Assess
Structure of human SRC regulatory domains in complex with the C-terminal PRRP motifs of GPR54.monomer87-247
Assess
Triple mutant Src SH2 domain bound to phosphotyrosinemonomer144-251
PTR;
Assess
Triple mutant Src SH2 domainmonomer144-251
Assess
Triple mutant Src SH2 domain bound to phosphate ionmonomer144-251
PO4;
Assess
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU82197.monomer145-250
197;
Assess
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU82129.monomer145-250
821;
Assess
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU85053.monomer145-250
853;
Assess
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH DPI59.monomer145-250
I59;
Assess
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH PASBN.monomer145-250
PSN;
Assess
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH OXALIC ACID.monomer145-250
OXD;
Assess
Crystal structure of sh2 in complex with ru85052monomer145-250
852;
Assess
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH ISO24.monomer145-250
IS2;
Assess
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU81843.monomer145-250
843;
Assess
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU79256.monomer145-250
256;
Assess
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU85493.monomer145-250
493;
Assess
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH PHENYLPHOSPHATE.monomer145-250
HPS;
Assess
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU78300.monomer145-250
300;
Assess
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH PAS219.monomer145-250
219;
Assess
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU84687.monomer145-250
687;
Assess
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU82209.monomer145-250
822;
Assess
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU83876.monomer145-250
876;
Assess
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU78299.monomer145-250
299;
Assess
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU90395.monomer145-250
903;
Assess
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU79072.monomer145-250
772;
Assess
NMR STRUCTURE OF THE HUMAN SRC SH2 DOMAIN COMPLEXmonomer144-249
Assess
NMR STRUCTURE OF THE HUMAN SRC SH2 DOMAIN COMPLEXmonomer144-249
Assess
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU78783.monomer145-249
787;
Assess
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH MALONICACID.monomer145-249
MLA;
Assess
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH FRAGMENT2.monomer145-249
CIT;
Assess
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH PHOSPHATE.monomer145-249
PO4;
Assess
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU78262.monomer145-249
262;
Assess
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU78791.monomer145-249
791;
Assess
PEPTIDE INHIBITORS OF SRC SH3-SH2-PHOSPHOPROTEIN INTERACTIONSmonomer145-249
Assess
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU79073.monomer145-249
790;
Assess
C-SRC (SH2 DOMAIN) COMPLEXED WITH ACE-DIFLUORO PHOSPHOTYR-GLU-(N,N-DIPENTYL AMINE)monomer145-249
Assess
Crystal structure of a superbinder Src SH2 domain (sSrcF) in complex with a high affinity phosphope…monomer147-250
ZN;
Assess

2 SWISS-MODEL models

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
2h8h.1.Amonomer0.8388-532
H8H;100.00
Assess
1y57.1.Amonomer0.8286-536
MPZ;100.00
Assess

4 SWISS-MODEL models built on isoform sequence

TemplateIsoformOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
Isoform 22h8h.1.Amonomer0.8288-538
H8H;100.00
Assess
Isoform 21y57.1.Amonomer0.8086-542
MPZ;100.00
Assess
Isoform 31y57.1.Amonomer0.7986-553
MPZ;100.00
Assess
Isoform 32h8h.1.Amonomer0.7888-549
H8H;100.00
Assess